in vivo animal testing - PowerPoint PPT Presentation

About This Presentation
Title:

in vivo animal testing

Description:

Electroporation transfer is emerged as a powerful tool for the genetic modification of diverse cell types based on the transient disruption of cell membrane via exposure to an electric field, which allows charged molecules to enter the cell. For instance, the square-wave pulse-based new electroporation devices, such as Lonza Nucleofector II electroporation system, manifests a high efficiency in the genetic modification of T cells with proprietary electroporation buffers and electric parameters. – PowerPoint PPT presentation

Number of Views:164

less

Transcript and Presenter's Notes

Title: in vivo animal testing


1
CAR-T Preclinical In Vivo Assay
  • Reference https//www.creative-biolabs.com/car-t/
    car-t-preclinical-in-vivo-assay.htm

2
Introduction
  • CAR-T cells are autologous or allogeneic T cells
    targeting specifically to antigens or markers
    expressed by tumor cells. In vivo assessment is
    of pivotal importance for investigating the
    factors that may affect the efficacy of CAR-T
    cells. The approaches of delivering CAR genes
    into T cells, the in vitro culture conditions,
    the constituents of the CAR construct, and the
    types of host T cells all have great impacts on
    CAR-T efficacy and safety. Data from in vivo
    assays is valuable for CAR-T optimization.

3
What can CAR-T cells do?
  • CAR-T cells capable of recognizing various
    tumor-associated antigens (TAAs) have been tested
    in many clinical trials and received plenty of
    encouraging results. However, several potential
    risks such as cytokine storm have also been posed
    for CAR-T cell clinical application. Therefore,
    preclinical in vivo assessment of the efficacy
    and safety of CAR-T cells are essential for
    dosage determination and risk managements for
    this promising immunotherapy against cancers.

4
How to conduct in vivo assays?
  • CAR-T cell preclinical in vivo animal testing
    performed in xenograft murine models derived by
    well-defined cell lines or primary human tumor
    cells.
  • Immunodeficient mice, lacking of effective innate
    immunity for the absence of B cells, T cells, or
    NK cells, are the optimal animal models for
    engraftment of tumor cells and evaluation of
    CAR-T cells.
  • The progression and remission of tumor cells
    detected in any body part throughout the whole
    treatment duration, obtaining an unambiguous
    evaluation of the therapeutic efficacy of CAR-T
    cells.
  • A series of studies to investigate several
    potential safety concerns of CAR-T therapy
    including inappropriate immune activation
    (cytokine level), the potential for
    tumorigenicity, the risks of the delivery
    procedure, etc.
  • The in vivo expansion, survival, persistence,
    migration, and distribution of the CAR-T cells
    are also systematically studied.

5
Featured in vivo Assay Categories
  • Construction of Xenograft Animal Model
  • Strategies to Harness Cytokine Release Syndrome
  • Efficacy Test of CAR-T
  • Viability and Bio-distribution Study of CAR-T
  • Toxicity Evaluation of CAR-T
  • Quality Control for in Vivo Assays

6
Targets for CAR-T Preclinical in vivo Assays
7
(No Transcript)
8
Thanks
  • Reference https//www.creative-biolabs.com/car-t/
    car-t-preclinical-in-vivo-assay.htm
Write a Comment
User Comments (0)
About PowerShow.com